Advanced Science. Uncovering Risk.
Matching patients to optimal treatments through molecular age signatures
Clinicians often use a patient’s age to inform treatment decisions in a wide range of clinical scenarios. However, chronological age is an unreliable predictor of individual’s risk of disease of treatment-related adverse outcomes. An individual’s rate of aging is strongly influenced by environmental, genetic, and lifestyle factors which are not accounted for by chronological age alone. In contrast, biomarkers of molecular age provide a snapshot of the overall health and resiliency of the body, helping physicians to better know their patients and more accurately predict their health risks.
How we think of aging
Decline in physiologic reserve is a natural part of aging and is responsible for an increase in risk of disease and adverse treatment outcomes. HealthSpan Diagnostics has developed a test that quantifies physiologic reserve by measuring biomarkers that cause cellular aging. Expression of these biomarkers is personalized and based on genetic, lifestyle, and environmental factors. Individuals of the same age can have drastically different molecular age signatures and unique risk profiles.
AKI-SapereTM, is being clinically validated in a cardiovascular disease setting to identify patients at high risk for acute kidney injury, adverse cardiac outcomes, rehospitalization and death.
Expression of p16 aging biomarker is a powerful predictor of patient frailty and is being clinically validated in multiple clincal settings.